Larissa Sander Magalhães, Dianer Nornberg Strelow, Mariana Parron Paim, Taís da Silva Teixeira Rech, Letícia Devantier Krüger, Antonio Luiz Braga, José Sebastião Santos Neto, César Augusto Brüning, Cristiani Folharini Bortolatto
Anxiety disorders, characterized by high prevalence rates, cause psychiatric disabilities and are related to impairments in serotoninergic system function. Frequent anxiety recurrence, resistance, and drug adverse effects have driven searches for new therapies. We initially evaluated the anxiolytic-like activity of 3-selanyl-benzo[b]furan compounds (SeBZF1-5) (50 mg/kg, i.g.) in male Swiss mice using the light-dark test (LDT). The compound 3-((4-methoxyphenyl)selanyl)-2-phenylbenzofuran (SeBZF3) exhibited anxiolytic-like activity...
October 2, 2023: Pharmacology, Biochemistry, and Behavior